Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neramexane mesylate add-on therapy to opioids for bone metastases pain
2004-002520-18Phase 2Terminated
- Sponsor
- Merz
- Start
- Jan 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cancer pain and bone metastasis pain (CIBP) comparing Neramexane mesylate add-on with Placebo add-on (2 arms). Primary endpoints: Change in opioid consumption from baseline to week 8 and Change in pain intensity from baseline to week 8. Started Jan 2005; status: terminated.
02
Drugs
neramexane
03
Conditions
cancer painbone metastasis pain (CIBP)
Beyond the preview
Go deeper on 2004-002520-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002520-18.